Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
87% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. AEZS: No Debt )
AEZS' s 10-Year Cash to Debt Range
Min: 0.44   Max: No Debt
Current: No Debt

F-Score: 4
Z-Score: -5.78
M-Score: -7.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -444.96
AEZS's Operating margin (%) is ranked higher than
60% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. AEZS: -444.96 )
AEZS' s 10-Year Operating margin (%) Range
Min: -1448.42   Max: -8.58
Current: -444.96

-1448.42
-8.58
Net-margin (%) 110.36
AEZS's Net-margin (%) is ranked higher than
99% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. AEZS: 110.36 )
AEZS' s 10-Year Net-margin (%) Range
Min: -994.25   Max: 110.36
Current: 110.36

-994.25
110.36
ROE (%) 39.94
AEZS's ROE (%) is ranked higher than
98% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. AEZS: 39.94 )
AEZS' s 10-Year ROE (%) Range
Min: -278.54   Max: 39.94
Current: 39.94

-278.54
39.94
ROA (%) 11.51
AEZS's ROA (%) is ranked higher than
94% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. AEZS: 11.51 )
AEZS' s 10-Year ROA (%) Range
Min: -55.21   Max: 14.94
Current: 11.51

-55.21
14.94
ROC (Joel Greenblatt) (%) -2033.75
AEZS's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. AEZS: -2033.75 )
AEZS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2033.75   Max: -12.06
Current: -2033.75

-2033.75
-12.06
Revenue Growth (%) -54.30
AEZS's Revenue Growth (%) is ranked higher than
57% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. AEZS: -54.30 )
AEZS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 143.5
Current: -54.3

0
143.5
EBITDA Growth (%) -20.90
AEZS's EBITDA Growth (%) is ranked higher than
64% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. AEZS: -20.90 )
AEZS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 177.8
Current: -20.9

0
177.8
EPS Growth (%) -25.90
AEZS's EPS Growth (%) is ranked higher than
66% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. AEZS: -25.90 )
AEZS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 62
Current: -25.9

0
62
» AEZS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

AEZS Guru Trades in Q2 2013

Murray Stahl 17,083 sh (unchged)
Jim Simons 376,650 sh (-29.44%)
» More
Q3 2013

AEZS Guru Trades in Q3 2013

Jim Simons 444,250 sh (+17.95%)
Murray Stahl 17,083 sh (unchged)
» More
Q4 2013

AEZS Guru Trades in Q4 2013

Jim Simons 896,445 sh (+101.79%)
Murray Stahl Sold Out
» More
Q1 2014

AEZS Guru Trades in Q1 2014

Jim Simons 44,150 sh (-95.07%)
» More
» Details

Insider Trades

Latest Guru Trades with AEZS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about AEterna Zentaris Inc

Billionaires Hold Waning Biotechs 42% Off
Year 2013 has been called the year of the biotech return. According to BioTechNow, the sector is doing better than it has since 2007. One of the highlighted companies today, StemCells Inc. (STEM) just completed its successful IPO last week. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 5.90
AEZS's P/E(ttm) is ranked higher than
99% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AEZS: 5.90 )
AEZS' s 10-Year P/E(ttm) Range
Min: 3.01   Max: 17.95
Current: 5.9

3.01
17.95
P/B 4.10
AEZS's P/B is ranked higher than
78% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. AEZS: 4.10 )
AEZS' s 10-Year P/B Range
Min: 0.59   Max: 44.68
Current: 4.1

0.59
44.68
P/S 384.62
AEZS's P/S is ranked lower than
52% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. AEZS: 384.62 )
AEZS' s 10-Year P/S Range
Min: 0   Max: 391.3
Current: 384.62

0
391.3
EV-to-EBIT -0.56
AEZS's EV-to-EBIT is ranked higher than
74% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AEZS: -0.56 )
AEZS' s 10-Year EV-to-EBIT Range
Min: 3.8   Max: 27.2
Current: -0.56

3.8
27.2
Current Ratio 1.07
AEZS's Current Ratio is ranked higher than
51% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. AEZS: 1.07 )
AEZS' s 10-Year Current Ratio Range
Min: 1.07   Max: 50.67
Current: 1.07

1.07
50.67
Quick Ratio 1.07
AEZS's Quick Ratio is ranked higher than
54% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. AEZS: 1.07 )
AEZS' s 10-Year Quick Ratio Range
Min: 1.07   Max: 49
Current: 1.07

1.07
49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 118.00
AEZS's Price/Net Cash is ranked higher than
71% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. AEZS: 118.00 )
AEZS' s 10-Year Price/Net Cash Range
Min: 3.57   Max: 117
Current: 118

3.57
117
Price/Net Current Asset Value 39.30
AEZS's Price/Net Current Asset Value is ranked higher than
73% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. AEZS: 39.30 )
AEZS' s 10-Year Price/Net Current Asset Value Range
Min: 1.9   Max: 39
Current: 39.3

1.9
39
Price/Tangible Book 11.80
AEZS's Price/Tangible Book is ranked higher than
66% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. AEZS: 11.80 )
AEZS' s 10-Year Price/Tangible Book Range
Min: 1.06   Max: 85.23
Current: 11.8

1.06
85.23
Price/Median PS Value 1.20
AEZS's Price/Median PS Value is ranked higher than
57% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. AEZS: 1.20 )
AEZS' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 15.06
Current: 1.2

0.32
15.06
Price/Graham Number 7.90
AEZS's Price/Graham Number is ranked higher than
86% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AEZS: 7.90 )
AEZS' s 10-Year Price/Graham Number Range
Min: 0.98   Max: 7.8
Current: 7.9

0.98
7.8
Earnings Yield (Greenblatt) 12.40
AEZS's Earnings Yield (Greenblatt) is ranked higher than
81% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. AEZS: 12.40 )
AEZS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.7   Max: 26.2
Current: 12.4

3.7
26.2
Forward Rate of Return (Yacktman) -132.04
AEZS's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. AEZS: -132.04 )
AEZS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -193.7   Max: -8
Current: -132.04

-193.7
-8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AEZ.Canada, ET81.Germany
AEterna Zentaris, Inc., is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.
» More Articles for NAS:AEZS

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
comment on AEZS Oct 26 2011 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 29 2014
12 Analyst Stocks to Buy Under $10 With Huge Potential Upside Jul 19 2014
Coverage initiated on Aeterna Zentaris by H.C. Wainwright Jul 17 2014
Basket Of Biotech Bargains To Buy And Hold Jun 30 2014
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto Jun 11 2014
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto Jun 11 2014
Aeterna Zentaris announces workforce reduction and optimization program Jun 10 2014
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a... Jun 10 2014
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a... Jun 10 2014
Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial... Jun 02 2014
Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial... Jun 02 2014
Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in... May 22 2014
Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in... May 22 2014
Aeterna Zentaris appoints CEO David Dodd as Chairman of the Board May 12 2014
Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual... May 12 2014
Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual... May 12 2014
Aeterna Zentaris announces at the market issuance program May 09 2014
Aeterna Zentaris Announces At the Market Issuance Program May 09 2014
Aeterna Zentaris Announces At the Market Issuance Program May 09 2014
Aeterna Zentaris' (AEZS) CEO David Dodd on Q1 2014 Results - Earnings Call Transcript May 09 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide